RU96111003A - DERIVATIVES N-ACYL-2-ARYLCYCLOPROPYLMETYLAMINE, STIMULATING MELATONIN SYNTHESIS, PHARMACEUTICAL COMPOSITION, RADIOLIGAND AND METHOD OF TREATMENT - Google Patents

DERIVATIVES N-ACYL-2-ARYLCYCLOPROPYLMETYLAMINE, STIMULATING MELATONIN SYNTHESIS, PHARMACEUTICAL COMPOSITION, RADIOLIGAND AND METHOD OF TREATMENT

Info

Publication number
RU96111003A
RU96111003A RU96111003/04A RU96111003A RU96111003A RU 96111003 A RU96111003 A RU 96111003A RU 96111003/04 A RU96111003/04 A RU 96111003/04A RU 96111003 A RU96111003 A RU 96111003A RU 96111003 A RU96111003 A RU 96111003A
Authority
RU
Russia
Prior art keywords
methyl
trans
butanamide
cyclopropyl
methoxyphenyl
Prior art date
Application number
RU96111003/04A
Other languages
Russian (ru)
Other versions
RU2162076C2 (en
Inventor
Дж.Киви Дэниел
Ф.Паркер Майкл
Дж.Мэттсон Рональд
Джонсон GB Грэхам
Original Assignee
Бристоль-Мейерз Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/487,306 external-priority patent/US5596019A/en
Application filed by Бристоль-Мейерз Сквибб Компани filed Critical Бристоль-Мейерз Сквибб Компани
Publication of RU96111003A publication Critical patent/RU96111003A/en
Application granted granted Critical
Publication of RU2162076C2 publication Critical patent/RU2162076C2/en

Links

Claims (21)

1. Производные N-ацил-2-арилциклопропилметиламина формулы 1 или 11, стимулирующие синтез мелатонина:
Figure 00000001

Figure 00000002

в которой X - галоген, водород, С1-4алкил или OR5, где R5 представляет собой водород, С1-4перфторалкил, С1-4фторалкил, С1-4пердейтероалкил, С1-20алкил, С4-20алкциклоалкил, С2-20карбонитрилоалкил, С3-22карбоалкоксиалкил, С3-20алкенил, С3-20алкинил, С9-20аралкил, С9-20аралкенил, С9-20аралкинил, С2-20гидроксиалкил, С8-20арилоксиалкил, С7-20пиридилалкил или С6-20пиррилалкил; Y-водород или галоген; Z-водород, галоген, циано, арил, С7-20аралкил, С8-20аралкинил или С2-20алкамидо; R в обоих случаях является водородом, галогеном или С1-4алкилом; G - двухвалентный метилен, этилен или С1-4алкметиленовый фрагмент; R1 - водород, С1-4алкил или бензил; R2 - С1-6алкил, С2-6алкенил, С3-6циклоалкил, С2-4алкоксиалкил, С1-4трифторметилалкил, С2-8алкилтиоалкил или NR3R4, где R3 и R4 независимо друг от друга выбирают из водорода и С1-4алкила, но R3 и R4 не могут одновременно быть водородом.1. Derivatives of N-acyl-2-arylcyclopropylmethylamine of formula 1 or 11, stimulating the synthesis of melatonin:
Figure 00000001

Figure 00000002

in which X is halogen, hydrogen, C 1-4 alkyl or OR 5 , where R 5 is hydrogen, C 1-4 perfluoroalkyl, C 1-4 fluoroalkyl, C 1-4 perdeuteroalkyl, C 1-20 alkyl, C 4 -20 alkcycloalkyl, C 2-20 carbonitriloalkyl, C 3-22 carboalkoxyalkyl, C 3-20 alkenyl, C 3-20 alkynyl, C 9-20 aralkyl, C 9-20 aralkenyl, C 9-20 aralkynyl, C 2-20 hydroxyalkyl, C 8-20 aryloxyalkyl, C 7-20 pyridylalkyl or C 6-20 pyrrylalkyl; Y is hydrogen or halogen; Z-hydrogen, halogen, cyano, aryl, C 7-20 aralkyl, C 8-20 aralkynyl or C 2-20 alkamido; R in both cases is hydrogen, halogen or C 1-4 alkyl; G is a bivalent methylene, ethylene or C 1-4 alkmethylene fragment; R 1 is hydrogen, C 1-4 alkyl or benzyl; R 2 - C 1-6 alkyl, C 2-6 alkenyl, C 3-6 cycloalkyl, C 2-4 alkoxyalkyl, C 1-4 trifluoromethylalkyl, C 2-8 alkylthioalkyl or NR 3 R 4 where R 3 and R 4 are independently selected from hydrogen and C 1-4 alkyl, but R 3 and R 4 cannot simultaneously be hydrogen. 2. Соединение формулы 1, отличающееся тем, что R1 - водород, R2 - С1-6алкил, С2-6алкенил или С3-6циклоалкил, Y и Z - водород, X - метокси.2. The compound of formula 1, wherein R 1 is hydrogen, R 2 is C 1-6 alkyl, C 2-6 alkenyl or C 3-6 cycloalkyl, Y and Z are hydrogen, X is methoxy. 3. Соединение по п.2, которое выбирают из группы, включающей: (транс)-N-[[2-(3-метоксифенил)циклопропил] метил] бутанамид, (-)-(транс)-N-[[2-(3-метоксифенил)циклопропил] метил] бутанамид, (транс)-N-[[2-(3-метоксифенил)циклопропил]метил]пропанамид, (+)-(транс)-N-[[2-(3-метоксифенил)циклопропил] метил]бутанамид, (транс)-N-[[2-(3-метоксифенил)циклопропил] метил]ацетамид, (-)-(транс)-N-[[2-(3-метоксифенил)циклопропил]метил]-2-метилпропанамид. 3. The compound according to claim 2, which is selected from the group including: (trans) -N - [[2- (3-methoxyphenyl) cyclopropyl] methyl] butanamide, (-) - (trans) -N - [[2- (3-methoxyphenyl) cyclopropyl] methyl] butanamide, (trans) -N - [[2- (3-methoxyphenyl) cyclopropyl] methyl] propanamide, (+) - (trans) -N - [[2- (3-methoxyphenyl ) cyclopropyl] methyl] butanamide, (trans) -N - [[2- (3-methoxyphenyl) cyclopropyl] methyl] acetamide, (-) - (trans) -N - [[2- (3-methoxyphenyl) cyclopropyl] methyl ] -2-methylpropanamide. 4. Соединение по п.2, где один или несколько заместителей X, Y и Z являются галогеном. 4. The compound according to claim 2, wherein one or more of the substituents X, Y, and Z are halogen. 5. Соединение по п.4, которое выбирают из группы, включающей: (транс)-N-[[2-(4-хлор-3-метоксифенил)циклопропил] метил] бутанамид, (транс)-N-[[2-(4-хлор-5-метоксифенил)циклопропил] метил] бутанамид, (транс)-N-[[2-(2,4-дибром-5-метоксифенил)циклопропил] метил]бутанамид, (транс)-N-[[2-(4-иод-5-метоксифенил)циклопропил] метил] бутанамид, (-)-(транс)-N-[[2-(2-иод-3-метоксифенил)циклопропил]метил]бутанамид. 5. The compound according to claim 4, which is selected from the group including: (trans) -N - [[2- (4-chloro-3-methoxyphenyl) cyclopropyl] methyl] butanamide, (trans) -N - [[2- (4-chloro-5-methoxyphenyl) cyclopropyl] methyl] butanamide, (trans) -N - [[2- (2,4-dibromo-5-methoxyphenyl) cyclopropyl] methyl] butanamide, (trans) -N - [[ 2- (4-iodo-5-methoxyphenyl) cyclopropyl] methyl] butanamide, (-) - (trans) -N - [[2- (2-iodo-3-methoxyphenyl) cyclopropyl] methyl] butanamide. 6. Соединение по п.1, где R1 - водород, R2 - алкил, алкенил или циклоалкил, X и Y - водород, R5 - С2-20алкил, С9-20аралкил или С3-20алкенил.6. The compound according to claim 1, where R 1 is hydrogen, R 2 is alkyl, alkenyl or cycloalkyl, X and Y are hydrogen, R 5 is C 2-20 alkyl, C 9-20 aralkyl or C 3-20 alkenyl. 7. Соединение по п.6, которое выбирают из группы, включающей: (транс)-N-[[2-(3-[(этоксифенил)циклопропил] метил] бутанамид, (транс)-N-[[2-[(3-октилокси)фенил] циклопропил] метил] бутанамид, (транс)-N-[[2-[(3-децилокси)фенил] циклопропил] метил]бутанамид, (транс)-N-[[2-[(3-ундецилокси)фенил] циклопропил] метил] бутанамид, (транс)-N-[[2-[(3-додецилокси)фенил]циклопропил] метил] бутанамид, (транс)-N-[[2-[3-(гептилокси)фенил]циклопропил]метил] бутанамид, (транс)-N-[[2-[3-(нонилокси)фенил] циклопропил] метил]бутанамид, (транс)-N-[[2-[3-(2-пропенилокси)фенил] циклопропил] метил] бутанамид, (транс)-N-[[2-[3-(6-фенилгексил)окси] фенил] циклопропил] метил] бутанамид, (транс)-N-[[2-[3-[(7-фенилгептил)окси] фенил] циклопропил] метил] бутанамид, (транс)-N-[[2-[3-[(2-фенилэтил)окси] фенил] циклопропил] метил] бутанамид, (транс)-N-[[2-[3-[3-(3-метоксифенил)пропокси] фенил] циклопропил] метил] бутанамид. 7. The compound according to claim 6, which is selected from the group including: (trans) -N - [[2- (3 - [(ethoxyphenyl) cyclopropyl] methyl] butanamide, (trans) -N - [[2 - [( 3-octyloxy) phenyl] cyclopropyl] methyl] butanamide, (trans) -N - [[2 - [(3-decyloxy) phenyl] cyclopropyl] methyl] butanamide, (trans) -N - [[2 - [(3- undecyloxy) phenyl] cyclopropyl] methyl] butanamide, (trans) -N - [[2 - [(3-dodecyloxy) phenyl] cyclopropyl] methyl] butanamide, (trans) -N - [[2- [3- (heptyloxy) phenyl] cyclopropyl] methyl] butanamide, (trans) -N - [[2- [3- (nonyloxy) phenyl] cyclopropyl] methyl] butanamide, (trans) -N - [[2- [3- (2-propenyloxy) phenyl] cyclopropyl] methyl] butanamide, (tr ns) -N - [[2- [3- (6-phenylhexyl) oxy] phenyl] cyclopropyl] methyl] butanamide, (trans) -N - [[2- [3 - [(7-phenylheptyl) oxy] phenyl] cyclopropyl] methyl] butanamide, (trans) -N - [[2- [3 - [(2-phenylethyl) oxy] phenyl] cyclopropyl] methyl] butanamide, (trans) -N - [[2- [3- [3 - (3-methoxyphenyl) propoxy] phenyl] cyclopropyl] methyl] butanamide. 8. Способ лечения нарушений, связанных с циркадным ритмом, отличающийся тем, что он включает введение больному терапевтического количества соединения по п.1. 8. A method of treating disorders associated with circadian rhythm, characterized in that it comprises the administration to a patient of a therapeutic amount of a compound according to claim 1. 9. Фармацевтическая композиция, предназначенная для лечения нарушений, связанных с циркадным ритмом, отличающаяся тем, что она содержит фармацевтически приемлемый носитель и эффективное количество соединения формулы 1. 9. Pharmaceutical composition intended for the treatment of disorders associated with circadian rhythm, characterized in that it contains a pharmaceutically acceptable carrier and an effective amount of the compounds of formula 1. 10. Радиолиганд, включающий радиохимически замещенное соединение по п.1. 10. Radioligand, including radiochemically substituted compound according to claim 1. 11. Радиолиганд, включающий радиоиодированное соединение, получаемое из соединения по п.1. 11. Radioligand comprising a radio-iodized compound obtained from a compound according to claim 1. 12. Соединение по п.1, которое представляет собой (-)-(транс)-N-[[2-(2-иод-5-метоксифенил)циклопропил]метил]бутанамид. 12. The compound according to claim 1, which is (-) - (trans) -N - [[2- (2-iodo-5-methoxyphenyl) cyclopropyl] methyl] butanamide. 13. Соединение по п.1, которое представляет собой (-)-(транс)-N-[[2-(3-метоксифенил)циклопропил]метил]бутанамид. 13. The compound according to claim 1, which is (-) - (trans) -N - [[2- (3-methoxyphenyl) cyclopropyl] methyl] butanamide. 14. Соединение по п.1, которое представляет собой (транс)-N-[[2-(3-метоксифенил)циклопропил]метил]пропанамид. 14. The compound according to claim 1, which is (trans) -N - [[2- (3-methoxyphenyl) cyclopropyl] methyl] propanamide. 15. Соединение по п.1, которое представляет собой (транс)-N-[[2-(3-метоксифенил)циклопропил]метил]пропанамид. 15. The compound according to claim 1, which is (trans) -N - [[2- (3-methoxyphenyl) cyclopropyl] methyl] propanamide. 16. Соединение по п. 1, которое представляет собой (транс)-N-[[2-(4-хлор-3-метоксифенил)циклопропил]метил]бутанамид. 16. The compound according to claim 1, which is (trans) -N - [[2- (4-chloro-3-methoxyphenyl) cyclopropyl] methyl] butanamide. 17. Соединение по п.1, которое представляет собой (транс)-N-[[3-(3-метоксифенил)-2,2-дифтор-1-циклопроп-1-ил]метил]бутанамид. 17. The compound according to claim 1, which is (trans) -N - [[3- (3-methoxyphenyl) -2,2-difluoro-1-cycloprop-1-yl] methyl] butanamide. 18. Соединение по п.1, которое представляет собой (транс)-N-[[3-(3-метоксифенил)-2,2-дифтор-1-циклопроп-1-ил]метил] пропанамид. 18. The compound according to claim 1, which is (trans) -N - [[3- (3-methoxyphenyl) -2,2-difluoro-1-cycloprop-1-yl] methyl] propanamide. 19. Соединение по п. 1, которое представляет собой (транс)-N-[[2-(5-фтор-2-иодфенил)циклопроп-1-ил]метил]бутанамид. 19. The compound according to claim 1, which is (trans) -N - [[2- (5-fluoro-2-iodophenyl) cycloprop-1-yl] methyl] butanamide. 20. Соединение по п.1, которое выбирают из группы, включающей: (транс)-N-[[2-(3-хлорфенил)циклопроп-1-ил] метил] бутанамид, (транс)-N-[[2-(3-бромфенил)циклопроп-1-ил] метил] бутанамид, (-)-(транс)-N-[[2-(3-фторфенил)циклопропил] метил]бутанамид, (транс)-N-[[2-(2,5-дифторфенил)циклопроп-1-ил] метил] бутанамид, (транс)-N-[[2-(2-бром-5-фторфенил)циклопроп-1-ил]метил] бутанамид, (транс)-N-[[2-(3-метилфенил)циклопроп-1-ил]метил]бутанамид, (транс)-N-[[2-[(3-этилфенил)циклопроп-1-ил] метил]бутанамид, (транс)-N-[[2-[(3-(трифторметокси)фенил]циклопроп-1-ил]метил]бутанамид. 20. The compound according to claim 1, which is selected from the group including: (trans) -N - [[2- (3-chlorophenyl) cycloprop-1-yl] methyl] butanamide, (trans) -N - [[2- (3-Bromophenyl) cycloprop-1-yl] methyl] butanamide, (-) - (trans) -N - [[2- (3-fluorophenyl) cyclopropyl] methyl] butanamide, (trans) -N - [[2- (2,5-difluorophenyl) cycloprop-1-yl] methyl] butanamide, (trans) -N - [[2- (2-bromo-5-fluorophenyl) cycloprop-1-yl] methyl] butanamide, (trans) - N - [[2- (3-methylphenyl) cycloprop-1-yl] methyl] butanamide, (trans) -N - [[2 - [(3-ethylphenyl) cycloprop-1-yl] methyl] butanamide, (trans) -N - [[2 - [(3- (trifluoromethoxy) phenyl] cycloprop-1-yl] methyl] butanamide. 21. Соединение по п.1, которое выбирают из группы, включающей: (цис)-N-[3-(3-метоксифенил)циклогексил] ацетамид, (цис)-N-[3-(3-метоксифенил)циклогексил]-2-метил-пропанамид, (цис)-N-[3-(3-метоксифенил)циклогексил] бутанамид, (цис)-N-этил-N'-[3-(3-метоксифенил)циклогексил]мочевину, -N-[3-(3-метоксифенил)циклопентил]бутанамид. 21. The compound according to claim 1, which is selected from the group comprising: (cis) -N- [3- (3-methoxyphenyl) cyclohexyl] acetamide, (cis) -N- [3- (3-methoxyphenyl) cyclohexyl] - 2-methyl-propanamide, (cis) -N- [3- (3-methoxyphenyl) cyclohexyl] butanamide, (cis) -N-ethyl-N '- [3- (3-methoxyphenyl) cyclohexyl] urea, -N- [3- (3-methoxyphenyl) cyclopentyl] butanamide.
RU96111003/04A 1995-06-07 1996-06-06 Derivatives of n-acyl-2-arylcycloalkylamine stimulating melatonin synthesis, pharmaceutical composition, method of melatonin-stimulating binding RU2162076C2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48663395A 1995-06-07 1995-06-07
US486,633 1995-06-07
US08/487,306 US5596019A (en) 1995-06-07 1995-06-07 N-acyl-cycloalkylamine derivatives as melatonergics
US487,306 1995-06-07

Publications (2)

Publication Number Publication Date
RU96111003A true RU96111003A (en) 1998-09-27
RU2162076C2 RU2162076C2 (en) 2001-01-20

Family

ID=27048750

Family Applications (1)

Application Number Title Priority Date Filing Date
RU96111003/04A RU2162076C2 (en) 1995-06-07 1996-06-06 Derivatives of n-acyl-2-arylcycloalkylamine stimulating melatonin synthesis, pharmaceutical composition, method of melatonin-stimulating binding

Country Status (23)

Country Link
EP (1) EP0747346B1 (en)
JP (1) JPH08333314A (en)
KR (1) KR100385360B1 (en)
CN (1) CN1068583C (en)
AR (1) AR003139A1 (en)
AT (1) ATE189807T1 (en)
AU (1) AU697028B2 (en)
CA (1) CA2176854A1 (en)
CY (1) CY2221B1 (en)
CZ (1) CZ291380B6 (en)
DE (1) DE69606665T2 (en)
DK (1) DK0747346T3 (en)
ES (1) ES2144666T3 (en)
GR (1) GR3033414T3 (en)
HK (1) HK1014704A1 (en)
HU (1) HUP9601565A3 (en)
IL (1) IL118427A (en)
NO (1) NO311211B1 (en)
NZ (1) NZ286640A (en)
PL (1) PL314671A1 (en)
PT (1) PT747346E (en)
RU (1) RU2162076C2 (en)
TW (1) TW350836B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030337B2 (en) 2006-06-19 2011-10-04 Takeda Pharmaceutical Company Limited Tricyclic compound and pharmaceutical use thereof

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856529A (en) * 1996-12-10 1999-01-05 Bristol-Myers Squibb Company Benzofuran and dihydrobenzofuran melatonergic agents
US6028112A (en) * 1997-05-23 2000-02-22 Bristol-Myers Squibb Company Spirocyclopropyl fluorenes as melatonergic agents
US6214869B1 (en) * 1998-06-05 2001-04-10 Bristol-Myers Squibb Heterocyclic cis cyclopropane derivatives as melatonergic agents
WO2000000459A1 (en) * 1998-06-29 2000-01-06 Mitsubishi-Tokyo Pharmaceuticals, Inc. Process for the preparation of optically active trans-cyclohexylamine compounds
FR2784375B1 (en) * 1998-10-12 2000-11-24 Adir NOVEL CYCLOALKYLENIC CHAIN DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2000021910A2 (en) * 1998-10-14 2000-04-20 Ortho-Mcneil Pharmaceutical, Inc. 1,2-disubstituted cyclopropanes
PE20020665A1 (en) * 2000-06-15 2002-08-14 Pharmacia Corp CYCLOALKYL PHENYL ALCANOIC ACID AS ANTAGONIST OF INTEGRINS OVß3
US7541055B2 (en) * 2004-09-10 2009-06-02 International Flavors & Fragrances Inc. Saturated and unsaturated N-alkamides exhibiting taste and flavor enhancement effect in flavor compositions
WO2007025144A1 (en) * 2005-08-24 2007-03-01 University Of Illinois - Chicago 5-ht2c receptor agonists as anorectic agents
US8835472B2 (en) * 2010-09-02 2014-09-16 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
MX2014014010A (en) * 2012-05-18 2015-02-12 Vanda Pharmaceuticals Inc Metabolites of (1r-trans)-n-[[2-(2,3-dihydro-4-benzofuranyl)cyclo propyl]methyl]propanamide.
CN102863341B (en) * 2012-10-22 2014-05-07 南通大学 Chemical synthesis method of (1R, 2S)-2-aryl cyclopropylamine derivative
WO2016123164A1 (en) * 2015-01-29 2016-08-04 The Board Of Trustees Of The University Of Illinois Cyclopropylmethanamines as selective 5-ht(2c) receptor agonists
CN105949153B (en) * 2016-05-10 2018-03-02 浙江工业大学 A kind of Ta Simeiqiong synthetic method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1415997A (en) * 1963-11-05 1965-10-29 Whitefin Holding Sa Phenylcyclopropane derivatives and methods of preparation
US5071875A (en) * 1989-09-25 1991-12-10 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
JP3007138B2 (en) * 1990-11-27 2000-02-07 ファイザー製薬株式会社 Novel hydroxamic acid and N-hydroxyurea derivatives and compositions thereof
FR2680366B1 (en) * 1991-08-13 1995-01-20 Adir NOVEL ARYLETHYLAMINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
JP3333510B2 (en) * 1991-10-02 2002-10-15 スミスクライン・ビーチャム・コーポレイション Cyclopentane and cyclopentene derivatives having antiallergic, antiinflammatory and tumor necrosis factor inhibitory activities
US5541228A (en) * 1994-10-14 1996-07-30 Bristol-Myers Squibb Co. Melatonergic agents

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030337B2 (en) 2006-06-19 2011-10-04 Takeda Pharmaceutical Company Limited Tricyclic compound and pharmaceutical use thereof
US8236837B2 (en) 2006-06-19 2012-08-07 Takeda Pharmaceutical Company Limited Tricyclic compound and pharmaceutical use thereof
US8349879B2 (en) 2006-06-19 2013-01-08 Takeda Pharmaceutical Company Limited Tricyclic compound and pharmaceutical use thereof
US8552037B2 (en) 2006-06-19 2013-10-08 Takeda Pharmaceutical Company Limited Tricyclic compound and pharmaceutical use thereof
US8895591B2 (en) 2006-06-19 2014-11-25 Takeda Pharmaceutical Company Limited Tricyclic compound and pharmaceutical use thereof

Similar Documents

Publication Publication Date Title
RU96111003A (en) DERIVATIVES N-ACYL-2-ARYLCYCLOPROPYLMETYLAMINE, STIMULATING MELATONIN SYNTHESIS, PHARMACEUTICAL COMPOSITION, RADIOLIGAND AND METHOD OF TREATMENT
RU98117314A (en) TROPANIC DERIVATIVES, THEIR PRODUCTION AND APPLICATION
JP2003528095A5 (en)
RU2003116648A (en) SUBSTITUTED IMIDAZOPYRIDINES
RU94044671A (en) Use of nonpeptide antagonists of tachykinin receptors
RU2004104625A (en) ANALOGUES OF PROSTAGLANDINS AS EP4 RECEPTOR AGONISTS
RU2004138819A (en) JAK AND CDK2 PROTEINKINASE INHIBITORS
RU2008123376A (en) 4- (4-ALCOXY-3-HYDROXYPHENYL) -2-pyrrolidone derivatives as PDE-4 INHIBITORS FOR TREATMENT OF NEUROLOGICAL SYNDROMES
RU2007101685A (en) MODULATORS OF NICOTINE ACETYLCHOLINE ALPHA 7 RECEPTORS AND THEIR THERAPEUTIC APPLICATIONS
RU2002103302A (en) Derivatives of N- (Indolecarbonyl) piperazine
RU95106675A (en) 3-indolyl piperidines, process for preparation thereof, pharmaceutical composition, and process for preparation thereof
KR970001306A (en) Fragrant Melatoninic N-acyl-2-aryl Cycloalkylmethylamine Derivatives and Pharmaceutical Compositions Comprising the Same
RU2001126570A (en) Derivatives of 1-arensulfonyl-2-arylpyrrolidine and piperidine for the treatment of disorders of the central nervous system
SE9601110D0 (en) Substituted 1,2,3,4-tetrahydronaphthalene derivatives
RU2005101876A (en) Derivatives of amino alcohols
RU97114793A (en) 2-AMINOINDANES AS DOPAMINE D3 SELECTIVE LIGANDS
RU2004117543A (en) AMRIDES OF ANTRANILIC ACID AND THEIR APPLICATION AS AN INHIBITORS OF TYROSINKINASE RECEPTOR OF VASCULAR ENDOTHELIUM GROWTH FACTOR (VEGF)
KR101049694B1 (en) Alpha-aminoamide derivatives useful as antimigraine agents
RU2004107847A (en) Isoxazolopyridinones and their use in the treatment of Parkinson's disease
RU2004131651A (en) Phthalimide derivatives as monoamine oxidase inhibitors
RU98104276A (en) NEW CONDENSED Isoquinolines as Ligands for Dopamine Receptors
RU96117381A (en) NEUROPROTECTIVE COMPOUNDS
RU96102574A (en) NEW DERIVATIVES / 1-PHENYL-1-HETEROCYCLYL / ALKANA AND THEIR APPLICATION AS NEURO-PROTECTIVE AGENTS
ATE196080T1 (en) USE OF DIPHENYLETHANE DERIVATIVES FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF GLAUCOMA
RU2005102586A (en) 2,5-SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTAGONISTS IX CCR-3 RECEPTOR